0001209191-23-024724.txt : 20230418 0001209191-23-024724.hdr.sgml : 20230418 20230418190919 ACCESSION NUMBER: 0001209191-23-024724 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230417 FILED AS OF DATE: 20230418 DATE AS OF CHANGE: 20230418 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lian Brian CENTRAL INDEX KEY: 0001614578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 23828166 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-17 0 0001607678 Viking Therapeutics, Inc. VKTX 0001614578 Lian Brian C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 1 1 0 0 President & CEO 0 Common Stock, par value $0.00001 per share 2023-04-17 4 M 0 125000 2.15 A 2432963 D Common Stock, par value $0.00001 per share 2023-04-17 4 S 0 155000 20.4501 D 2277963 D Stock Option (Right to Buy) 2.15 2023-04-17 4 M 0 125000 0.00 D 2017-03-04 2026-03-04 Common Stock 125000 0 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person. 25% of the shares subject to the option vested on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2023-04-18